Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy

M S Piver; J Malfetano; T R Baker; R E Hempling

doi:10.1016/0090-8258(92)90232-8

Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy

Gynecol Oncol. 1992 Sep;46(3):357-60. doi: 10.1016/0090-8258(92)90232-8.

Authors

M S Piver¹, J Malfetano, T R Baker, R E Hempling

Affiliation

¹ Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263.

PMID: 1526515
DOI: 10.1016/0090-8258(92)90232-8

Abstract

Thirty-two stage IC or stage I grade 3 patients with invasive ovarian adenocarcinoma were treated with 6 months of adjuvant cisplatin-based chemotherapy. With a median follow-up of 60.5 months, there have been three (9%) recurrences. The 5-year progression-free survival was 90.5% and the 5-year survival was 93.3%.

MeSH terms

Adenocarcinoma / drug therapy
Adenocarcinoma / mortality
Adenocarcinoma / pathology
Carcinoma / drug therapy
Carcinoma / mortality
Carcinoma / pathology
Chemotherapy, Adjuvant
Cisplatin / therapeutic use*
Endometriosis / drug therapy
Endometriosis / mortality
Endometriosis / pathology
Female
Humans
Neoplasm Recurrence, Local
Neoplasm Staging
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / mortality
Ovarian Neoplasms / pathology
Prospective Studies

Substances

Cisplatin